Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients

OBJECTIVES: Emerging data suggest that the combination of tacrolimus and the CCR5 antagonist maraviroc, both cytochrome P450-3A4 substrates, may be effective in preventing graft-versus-host disease in patients undergoing allogeneic HSCT. This study evaluated whether a pharmacokinetic interaction exi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Antimicrob Chemother
Autors principals: Ganetsky, Alex, Miano, Todd A., Hughes, Mitchell E., Vonderheide, Robert H., Porter, David L., Reshef, Ran
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472330/
https://ncbi.nlm.nih.gov/pubmed/25881619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv082
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars